Medications

Dexamethasone still beneficial for some inpatients with COVID-19

Early administration of dexamethasone is associated with significantly reduced odds of mortality or discharge to hospice for inpatients with COVID-19 receiving supplemental oxygen or mechanical ventilation (MV) and/or extracorporeal ...

Medications

Survival benefit seen with triple therapy for severe COVID-19

For patients with severe COVID-19 requiring high flow nasal cannula (HFNC), triple therapy of dexamethasone, remdesivir, and baricitinib is associated with significant survival benefit compared with dual therapy, according ...

Medications

Study compares baricitinib to dexamethasone for COVID-19

For hospitalized patients with COVID-19 requiring supplemental oxygen, baricitinib plus remdesivir and dexamethasone plus remdesivir result in similar mechanical ventilation-free survival by day 29, but adverse events occur ...

Medications

COVID-19 therapies are better in combination than alone

There is a steadily growing arsenal of drugs for COVID-19. Researchers from Charité-Universitätsmedizin Berlin, the Max Delbrück Center for Molecular Medicine (MDC) and Freie Universität (FU) Berlin have studied the mechanisms ...

Medications

Dexamethasone enhances transgene expression

Dexamethasone, a glucocorticoid with anti-inflammatory and immunosuppressive effects, can transiently increase the expression of therapeutic genes delivered using adeno-associated virus (AAV) vectors. A new study, which showed ...

page 1 from 8

Dexamethasone

Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs. It acts as an anti-inflammatory and immunosuppressant. It is 20 to 30 times more potent than the naturally occurring hormone cortisol and 4 to 5 times more potent than prednisone.

This text uses material from Wikipedia, licensed under CC BY-SA